Linker Information
General Information of This Linker
| Linker ID |
LIN0PKVWK
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
L27 linker
|
|||||
| Linker Type |
Beta-glucuronide based linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C182H318N16O90
|
|||||
| Isosmiles |
OC1=CC(NC(CCNC([C@@H](NC(OCCN2N=NC(COC(N[C@@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCN3C(C=CC3=O)=O)=O)C(N[C@H](C(NCCC(NC4=C(O[C@H]5[C@H](O)[C@@H](O)C(O)=C(O5)C(O)=O)C=CC(O)=C4)=O)=O)CCCCNC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(O)=O)=O)=O)=O)=C2)=O)CCCCNC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(O)=O)=O)=O)=O)=C(O[C@H](O6)[C@H](O)[C@@H](O)[C@H](O)[C@@H]6C(O)=O)C=C1
|
|||||
| InChI |
InChI=1S/C182H318N16O90/c199-148-10-12-155(285-177-168(214)164(210)166(212)170(287-177)175(219)220)153(143-148)190-158(202)16-24-184-172(216)150(7-2-5-22-186-179(223)188-26-33-230-40-46-236-52-58-242-64-70-248-76-81-253-85-89-257-93-97-261-101-105-265-109-113-269-117-121-273-125-129-277-133-137-281-141-139-279-135-131-275-127-123-271-119-115-267-111-107-263-103-99-259-95-91-255-87-83-251-79-74-246-68-62-240-56-50-234-44-38-228-31-19-162(206)207)192-174(218)152(9-1-4-21-183-157(201)18-30-227-37-43-233-49-55-239-61-67-245-73-78-250-72-66-244-60-54-238-48-42-232-35-29-198-160(204)14-15-161(198)205)194-182(226)284-146-147-145-197(196-195-147)28-36-283-181(225)193-151(173(217)185-25-17-159(203)191-154-144-149(200)11-13-156(154)286-178-169(215)165(211)167(213)171(288-178)176(221)222)8-3-6-23-187-180(224)189-27-34-231-41-47-237-53-59-243-65-71-249-77-82-254-86-90-258-94-98-262-102-106-266-110-114-270-118-122-274-126-130-278-134-138-282-142-140-280-136-132-276-128-124-272-120-116-268-112-108-264-104-100-260-96-92-256-88-84-252-80-75-247-69-63-241-57-51-235-45-39-229-32-20-163(208)209/h10-15,143-145,150-152,164-165,167-169,171,177-178,199-200,210-215H,1-9,16-142,146H2,(H,183,201)(H,184,216)(H,185,217)(H,190,202)(H,191,203)(H,192,218)(H,193,225)(H,194,226)(H,206,207)(H,208,209)(H,219,220)(H,221,222)(H2,186,188,223)(H2,187,189,224)/t150-,151-,152-,164-,165-,167-,168+,169+,171+,177+,178+/m0/s1
|
|||||
| InChIKey |
JRZWFSOVPDIXLA-POESQJAJSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
4170.568
|
Polar area
|
1266.45
|
||
|
Complexity
|
.
|
xlogp Value
|
-3.8446
|
|||
|
Heavy Count
|
288
|
Rot Bonds
|
217
|
|||
|
Hbond acc
|
89
|
Hbond Donor
|
24
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
CD74 Milatuzumab DANAPAE152C S375C-P1-L27-P1 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.269 nM
|
High CD74 expression (CD74 +++) | ||
| Method Description |
CD74 Milatuzumab DANAPAE152C S375C-P1-L27-P1 was tested in EOL-1
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||